Cardioloxía
Servicio
University of Lorraine
Nancy, FranciaPublicacións en colaboración con investigadores/as de University of Lorraine (9)
2023
-
Fulminant myocarditis proven by early biopsy and outcomes
European Heart Journal, Vol. 44, Núm. 48, pp. 5110-5124
2022
-
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520
-
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45
-
Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry
European Heart Journal, Vol. 43, Núm. 29, pp. 2770-2780
2021
-
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116
-
Empagliflozin in heart failure with a preserved ejection fraction
New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461
2020
-
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392
-
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171
-
Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry
European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1378-1389